

09986797 34304
The present invention relates to new
recombinant viruses, to their preparation and to their
5 use in gene therapy for the transfer of genes to the
eye and their expression therein. It also relates to
pharmaceutical compositions comprising the said
recombinant viruses. More especially, the present
invention relates to defective recombinant viruses and
10 to their use for the treatment of ocular pathologies.

The treatment of ocular pathologies, and in
particular of hereditary diseases, constitutes a
problem which has not been solved at the present time.
Among these pathologies, there may be mentioned, for
15 example, retinitis pigmentosa, which results from
adverse genetic modifications and for which no
treatment is currently available. Moreover, no suitable
treatment is at present available either for non-
hereditary pathologies such as post-inflammatory
20 complaints (retinal degeneration, and the like). In
particular, while an effort is made to act
preventively, in particular using corticoids, no
satisfactory means for treating these complaints is
currently available.

25 It is hence important to be able to have
tools available permitting a specific, effective and
localized treatment of ocular pathologies. The present
invention provides an advantageous approach to this

problem, by demonstrating the possibility of treating ocular pathologies by gene therapy.

Gene therapy consists in correcting a deficiency or an abnormality (mutation, aberrant expression, and the like) by introduction of genetic information into the affected cell or organ. This genetic information may be introduced either in vitro into a cell extracted from the organ, the modified cell then being reintroduced into the body, or directly in vivo into the appropriate tissue. In this second case, different techniques exist, including various transfection techniques involving complexes of DNA and DEAE-dextran (Pagano et al., J.Virol. 1 (1967) 891), of DNA and nuclear proteins (Kaneda et al., Science 243 (1989) 375), of DNA and lipids (Felgner et al., PNAS 84 (1987) 7413), the use of liposomes (Fraley et al., J. Biol. Chem. 255 (1980) 10431), and the like. More recently, the use of viruses as vectors for the transfer of genes has appeared as a promising alternative to these physical transfection techniques. In this connection, different viruses have been tested for their capacity to infect certain cell populations. These comprise, in particular, retroviruses (RSV, HMS, MMS, and the like), the HSV virus, adeno-associated viruses and adenoviruses.

However, hitherto, none of these vectors has been used or described as being usable for the transfer of genes to the eye. The present invention constitutes

0986797.44304
FBI/DOJ

the first demonstration that it is possible to treat ocular pathologies by gene therapy.

A first subject of the invention lies in the use of a defective recombinant virus containing an inserted gene for the preparation of a pharmaceutical composition intended for the treatment of ocular pathologies.

More especially, defective recombinant viruses derived from viruses capable of infecting and of expressing an inserted gene in the cells of the eye, without giving rise to cytopathological phenomena or pathogenic effects, are used according to the present invention. Viruses capable of being used in the invention are, for example, adenoviruses, adeno-associated viruses or alternatively the HSV virus.

The present invention is based more especially on the demonstration that adenovirus type viruses are capable of transferring desired genes to the eye and of expressing them therein. The examples presented later show that adenoviruses are capable, depending on the mode of administration, of transferring genes to the corneal endothelium, to photoreceptor cells, to cells of the optic nerve, to bipolar cells, and the like, effectively, for a considerable period and without a cytopathological effect. Moreover, in view of the relative ease of access to the different compartments of the eye by microsurgery (microinjection), as well as of the

09086797-11301

existence natural barriers in this organ (Descemet's membrane, Bruch's membrane, lens, and the like), the present invention advantageously enables a very targeted transfer of genes to be performed, in accordance with the pathology to be treated. The results presented also show that the expression of a desired gene is stable over a long period (no loss of activity at 50 days).

In a preferred embodiment, the invention lies in the use of a defective recombinant adenovirus containing an inserted gene for the preparation of a pharmaceutical composition intended for the treatment of ocular pathologies.

The term "defective virus or adenovirus" denotes a virus incapable of replicating autonomously in the target cell. Generally, the genome of the defective viruses used in the context of the present invention hence lacks at least the sequences needed for replication of the said virus in the infected cell.

These regions may be either removed (wholly or partially), or rendered non-functional, or replaced by other sequences, and in particular by the inserted gene. Preferably, the defective virus nevertheless retains the sequences of its genome which are needed for encapsidation of the viral particles.

Regarding, more especially, adenoviruses, the latter exist in the form of different serotypes, whose structure and properties vary somewhat. Nevertheless,

09986797 "11301

these viruses are not pathogenic for man, and in particular non-immunosuppressed subjects. Among these serotypes, it is preferable, in the context of the present invention, to use adenovirus type 2 or 5 (Ad 2 or Ad 5). In the case of adenoviruses Ad 5, the sequences needed for replication are the E1A and E1B regions.

Defective recombinant viruses derived from retroviruses, from adeno-associated viruses or from the HSV virus (herpes simplex virus) have already been described in the literature [Roemer and Friedmann, Eur. J. Biochem. 208 (1992) 211; Dobson et al., Neuron 5 (1990) 353; Chiocca et al., New Biol. 2 (1990) 739; Miyanojara et al., New Biol. 4 (1992) 238; WO91/18088].

For the purposes of the present invention, the term "inserted gene" denotes any DNA sequence introduced into the recombinant virus, whose expression in the target cell is sought.

It can be, in particular, one (or more) structural gene(s) coding for a (some) protein(s) or for a portion of a (some) protein(s). The protein or protein portion thus encoded can be a protein which is homologous with respect to the target cell (that is to say a protein which is normally expressed in the target cell when the latter does not exhibit any pathology), or a protein which is heterologous with respect to the said cell. In the former case, expression of the protein makes it possible, for example, to remedy an

09936797.11304

insufficient expression in the cell or the expression of a protein which is inactive or poorly active as a result of a modification, or alternatively to overexpress the said protein. In the second case, the protein expressed can, for example, supplement or supply an activity which is deficient in the cell, enabling it to combat a pathology.

Among inserted genes for the purposes of the present invention, there may be mentioned, more especially:

- genes involved in ocular genetic pathologies,
- genes coding for growth factors, cytokines or neurotrophins: the protective or curative role of the expression product of these genes in different ocular pathologies has been demonstrated, and in particular on the deterioration of photoreceptor cells under the effect of light (Lavail et al., PNAS 89 (1992) 11249),
- genes for regulatory factors (transcription factors, translation factors),
- genes coding for enzymes,
- genes coding for proteins having anticancer properties, such as interferons, tumour necrosis factors, and the like, or alternatively,
- genes coding for antigens permitting a local vaccination (protection) against an eye infection.

09080797.11304

As specific, but non-limiting, examples,
there may be mentioned:

- the ornithine aminotransferase gene involved in gyrate atrophy (Akaki et al., J. Biol. Chem. 267 (18) (1992) 12950),
- the rhodopsin gene involved in a form of retinitis pigmentosa (Dryja et al., Nature 343 (1990) 364),
- the RDS peripherin gene involved in a form of retinitis pigmentosa (Farrar et al., Nature 354 (1991) 478),
- the tyrosinase gene involved in type B1 oculocutaneous albinism (Giebel et al., Am. J. Hum. Genet. 48 (1991) 1159),
- the mitochondrial NDI gene involved in Leber's disease (Howell et al., Am. J. Hum. Genet. 48 (1991) 935),
- the gene for the β subunit of cGMP phosphodiesterase, which enables retinal degeneration to be slowed down (Lem et al., PNAS 89 (1992) 4422),
- the rab geranylgeranyl transferase gene, the deficiency of which appears to be associated with a retinal degeneration in choroideremia (Seabra et al., Science 259 (1993) 377),
- the basic fibroblast growth factor (bFGF) gene, capable of retarding the degeneration of the photoreceptor cells which is observed in some

090679 11301
F00000 16298660

hereditary retinal dystrophies (Faktorovich et al.,
Nature 347 (1990) 83),

- the interleukin-8 gene, which enables a neovascularization to be induced in the cornea
- 5 (Strieter et al., Am. J. Pathol. 141 (6) (1992) 1279).

The term "inserted gene" also denotes antisense sequences, whose expression in the target cell enables the expression of genes or the transcription of cellular mRNAs to be controlled. Such
10 sequences can, for example, be transcribed in the target cell into RNAs complementary to cellular mRNAs and can thus block their translation into protein.

Generally, the inserted gene also comprises sequences permitting its expression in the infected
15 cell. The sequences in question can be ones which are naturally responsible for expression of the said gene when these sequences are capable of functioning in the infected cell. They can also be sequences of different origin (responsible for the expression of other
20 proteins, or even synthetic sequences). In particular, they can be sequences originating from the genome of the cell which it is desired to infect, or from the genome of the virus used. In the case of adenoviruses, there may be mentioned, for example, the promoters of
25 the E1A, MLP genes, and the like. In addition, these expression sequences may be modified by the addition of activation, regulatory, and the like, sequences. Moreover, when the inserted gene does not contain

09086797 45498660

expression sequences, it may be inserted into the genome of the defective virus downstream of such a sequence.

In what follows, the construction and use of defective recombinant adenoviruses are described in greater detail. It is nevertheless understood that this description may be applied by a person skilled in the art to other viruses capable of being used in the context of the present invention, as mentioned above.

Defective recombinant adenoviruses may be prepared by homologous recombination between an adenovirus and a plasmid carrying, inter alia, the gene which it is desired to insert. Homologous recombination takes place after cotransfection of the said adenovirus and said plasmid into a suitable cell line. The cell line used should preferably (i) be transformable by the said elements, and (ii) contain the sequences capable of complementing the portion of the genome of the defective adenovirus, preferably in integrated form in order to avoid the risks of recombination. As an example of a line, there may be mentioned the human embryonic kidney line 293 (Graham et al., J. Gen. Virol. 36 (1977) 59), which contains, in particular, integrated in its genome, the left-hand portion of the genome of an adenovirus Ad 5 (12 %).

Thereafter, the vectors which have multiplied are recovered and purified according to standard techniques of molecular biology.

The present invention also relates to a pharmaceutical composition comprising a sufficient amount of defective recombinant virus as defined above, in a form suitable for ocular administration.

5 In particular, the defective recombinant
virus may be in the form of an injection, eye lotion,
ophthalmic ointment, and the like. The pharmaceutically
acceptable vehicles for such formulations suitable for
ocular administration are, in particular, saline
10 solutions (monosodium or disodium phosphate, sodium,
potassium calcium or magnesium chloride, and the like,
or mixtures of such salts), soft paraffin, liquid
paraffin, and the like.

In the case of eye lotions or ophthalmic ointments, it is understood that the therapeutic applications may be more limited on account of a weaker diffusion of the defective recombinant virus.

In their use for the treatment of ocular pathologies, the defective recombinant viruses according to the invention may be administered according to different modes, and in particular by subretinal injection preceded, where appropriate, by a vitrectomy, or by intravitreal injection, the injections being single or multiple (see Figure 1).

Subretinal injection may be carried out selectively in different compartments of the eye, and, in particular, injection may be carried out in the vitreous, in the anterior chamber or in the retrobulbar space. The

results presented in the present application show that these different modes of injection enable the different tissues of the ey , and in particular th corneal endothelium, the photoreceptor cells, the bipolar
5 cells, the ganglion cells or alternatively the cells of the oculomotor muscles, to be infected in a targeted manner.

The doses of virus used for the injection may be adapted in accordance with different parameters, and
10 in particular in accordance with the mode of administration used, the pathology in question, the gene to be expressed or alternatively the period of treatment required. Generally speaking, the recombinant adenoviruses according to the invention are formulated
15 and administered in the form of doses of between 10^4 and 10^{14} pfu/ml, and preferably 10^6 to 10^{10} pfu/ml. The term pfu (plaque forming unit) corresponds to the infectious power of a solution of virus, and is determined by infection of a suitable cell culture and
20 measurement, generally after 48 hours, of the number of plaques of infected cells. The techniques of determination of the pfu titre of a viral solution are well documented in the literature.

In view of the stability of expression of the
25 inserted gene in the target cell, the present invention should make it possible to treat the majority of ocular pathologies with few injections.

The present invention thus affords a very

09986797 44304

effective means for the treatment of ocular pathologies, and in particular those whose mechanisms have been elucidated at molecular level. In particular, the involvement of genes has been demonstrated in

5 gyrate atrophy, in Norrie's disease (Hum. Mol. Genet. 1 (7) (1992) 461), in retinal degeneration (Bowes et al., PNAS 86 (1989) 9722) in Leber's disease, in choroideremia (Cremers et al., Nature 347 (1990) 674), in degeneration of photoreceptor cells, in retinitis

10 pigmentosa, in albinism, in Kearns-Sayre syndrome (Shoffner et al., PNAS 86 (1989) 7952), and the like. The present invention is also for the treatment of acquired adverse modification in the cornea resulting from inflammatory disorders, post-inflammatory retinal

15 complaints, and the like.

The present invention also makes possible therapy with proteins or peptides, the use of which via the traditional administration routes is very hypothetical on account of their great sensitivity to

20 the mechanisms of degradation and elimination from the body, and problems associated with penetration into the cells. The use of viruses according to the invention permits the direct expression, within the population of targeted cells, of the desired protein or polypeptide,

25 which is hence no longer accessible to the mechanisms mentioned above.

The collective results presented in the present application demonstrate, more especially, that

r combinant adenoviruses, which are defective for replication, constitute especially advantageous vectors for the transfer of genes in vivo to ocular cells. The experiments carried out show the possibility of a

5 stable long-term expression of genes in these cells. In particular, a stable expression is observed 50 days after injection. Furthermore, the broad spectrum of expression in the different ocular cells also constitutes an especially advantageous result, inasmuch

10 as practically all disorders of the retina (in particular retinitis pigmentosa) affect a large area of the retina.

In addition, this treatment can relate both to man and to any animal such as sheep, cattle,

15 domestic animals (dogs, cats, and the like), horses, fish, and the like.

The present invention is described more completely by means of the examples which follow, which are to be considered as illustrative and non-limiting.

20 Legend to the figures

Figure 1: Diagrammatic representation of the eye. C = cornea; AC = anterior chamber; L = lens; V = vitreous; I = iris; ON = optic nerve; R = retrobulbar space.

Construction of a defective recombinant adenovirus

25 (Ad.RSV β Gal):

The general procedure enabling recombinant adenoviruses to be prepared has been described in the general part of the description.

0986797.11301

Th adenovirus Ad.RSV β Gal is a defective recombinant adenovirus (from which the E1 and E3 regions have been deleted) obtained by homologous recombination in vivo between the mutant adenovirus Ad-d1324 (Thimmappaya et al., Cell 31 (1982) 543) and plasmid pAd.RSV β Gal (Akli et al., 1993).

Plasmid pAd.RSV β Gal contains, in the 5' \rightarrow 3' orientation,

- the PvuII fragment corresponding to the left-hand end of the adenovirus Ad 5, comprising: the ITR sequence, the origin of replication, the encapsidation signals and the E1A amplifier;
- the gene coding for β -galactosidase under the control of the RSV (Rous sarcoma virus) promoter;
- a second fragment of the genome of the adenovirus Ad 5, which permits homologous recombination between plasmid pAd.RSV β Gal and the adenovirus d1324.

After linearization with the enzyme ClaI, plasmid pAd.RSV β Gal and the adenovirus d1324 are cotransfected into the line 293 in the presence of calcium phosphate to permit homologous recombination. The recombinant adenoviruses thus generated are selected by purification on plates. After isolation, the DNA of the recombinant adenovirus is amplified in the cell line 293, thereby leading to a culture supernatant containing the unpurified recombinant defective adenovirus having a titre of approximately

09086797-111301

10¹⁰ pfu/ml.

The viral particles are generally purified by centrifugation on a caesium chloride gradient according to known techniques (see, in particular, Graham et al., Virology 52 (1973) 456). The adenovirus Ad.RSV β Gal is stored at -80°C in 20 % glycerol. Before injection, the adenovirus suspension is diluted to one third in phosphate buffer PBS.

Injection in vivo

10 - Protocol

3- to 7-week-old C57B1/6 mice were anaesthetized with Avertin. 10⁷ to 10⁸ pfu of recombinant adenovirus Ad.RSV β Gal were then injected into each eye, either in the anterior chamber, or in the vitreous, or in the retrobulbar space (see Figure 1). The animals were sacrificed 7 to 50 days after injection by cervical dislocation, and the eyes were recovered and fixed in liquid nitrogen. Sagittal and coronal sections (10-15 μ m) are prepared on a cryostat, then stained in the presence of X-gal to disclose β -galactosidase activity, which may be visualized by the appearance of a blue stain in the nucleus of the infected cells, and counterstained with haematoxylin and eosin.

25 - Injection in the anterior chamber

After injection of 10⁸ pfu of adenovirus Ad.RSV β Gal in the space of the anterior chamber, only the cells of the endothelial layer express

5

- Intravitreal injections

10

15

20

25

Three nuclear layers, corresponding to the

ganglion, bipolar and photoreceptor cells, also exhibit an intense staining at three weeks (age at which development of the retina is complete), as well as in adult mice. Despite the presence of the signal

5 permitting the nuclear localization of the LacZ protein, the labelling (and hence infection) of some cells at the injection site is so intense that the staining diffuses into the cytoplasm. For this reason, the layer of nerve fibre corresponding to the axons of
10 the labelled nuclei (which converge to form the optic nerve) is labelled homogeneously.

A careful analysis of the different layers of retinal cells does not reveal any significant decrease in their thickness. Furthermore, the head of the optic
15 nerve is not adversely affected, even at high doses of adenovirus (10^7 pfu).

- Injection in the retrobulbar space

To evaluate the possibility of a diffusion of the virus through the sclera, mice were injected in the
20 retrobulbar space. In contrast to the retinal staining, approximately 100 % of the fibres of the 4 oculomotor muscles were infected and express β -galactosidase activity.

These collective results clearly demonstrate
25 that recombinant adenoviruses which are defective for replication constitute especially advantageous vectors for the transfer of genes in vivo to ocular cells.

09986797.11301